Dr. Grossman’s Blog

In the first study, Jennifer S.L. Tan, MBBS, BE at the University of Sydney, Australia and her colleagues evaluated data from 2,454 participants in the Blue Mountains Eye Study of men and women aged 49 and older. Those who consumed one serving of fish per week were shown to have a 31 percent lower adjusted risk of developing early AMD compared with those who consumed less.

In the second article, Elaine W. T. Chong, MD, PhD, of the Centre for Eye Research Australia and her associates evaluated data from 6,734 men and women aged 58 to 69 who participated in the Melbourne Collaborative Cohort Study. Dietary questionnaires completed between 1990 and 1994 were analyzed for the intake of various foods and individual fatty acids. Follow up examinations conducted between 2003 and 2006 detected 2,872 cases of early age-related macular degeneration and 88 cases of late disease.

A high intake of trans-unsaturated fats was associated with a significant increase in late macular degeneration, with those whose intake was categorized as among the top 25 percent of participants having a 76 percent greater risk than those whose intake was among the lowest fourth.

Olive oil emerged as protective against late disease. When those who reported consuming at least 100 milliliters per week olive oil were compared with those who consumed less than 1 milliliter per week, they were found to have a 52 percent lower risk of late AMD.

For early AMD, those whose omega-3 fatty acid intake was among the top 25 percent had a 15 percent lower risk compared with those whose intake was among the lowest quarter.

For more information on nutrition and macular degeneration and related research studies, see NaturalEyeCare’s Section on Macular Degeneration.

A team of scientists and surgeons from the Institute of Ophthalmology at University College London and the Moorfields Eye Hospital in London has developed a stem cell therapy to treat age-related macular degeneration (AMD), the most common cause of vision loss in the elderly.
“Under the new treatment, embryonic stem cells are transformed into replicas of the missing cells,” writes The Times of London. “They are then placed on an artificial membrane which is inserted in the back of the retina.”

Pharmaceutical giant Pfizer announced this week that it will fund the development of the therapy; UCL professor Pete Coffey, who led the research team, predicts the therapy will be available as part of a simple, one-hour procedure within six or seven years.The researchers are applying for approval to conduct a clinical trial on humans; it would be just the second-ever trial conducted on humans using embryonic stem cells. Laboratory trials completed by the British team have demonstrated that stem cells can prevent blindness in rats with a similar disease to AMD. They have also successfully tested elements of the technology in pigs.

For natural approaches to help prevent the onset of macular degeneration as well as help preserve vision for those with macular degeneration, visit the Natural Eye Care web site